A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

Hepatology

Volumn 65, Issue 3, 2017, Pages 950-968

  Valdecantos, M Pilar ^a,b   Pardo, Virginia ^a,b   Ruiz, Laura ^a,b   Castro Sánchez, Luis ^c   Lanzón, Borja ^d   Fernández Millán, Elisa ^b,e   García Monzón, Carmelo ^f,g   Arroba, Ana I ^a,b   González Rodríguez, Águeda ^f,g   Escrivá, Fernando ^b,e   Álvarez, Carmen ^b,e   Rupérez, Francisco J ^d   Barbas, Coral ^d   Konkar, Anish ^h   Naylor, Jacqui ⁱ   Hornigold, David ⁱ   Santos, Ana Dos ⁱ   Bednarek, Maria ⁱ   Grimsby, Joseph ^h   Rondinone, Cristina M ^h   Valverde, Ángela M ^a,b   more..

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD DE COLIMA   (Mexico)

^d UNIVERSIDAD SAN PABLO CEU   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h MEDIMMUNE   (United States)

ⁱ MEDIMMUNE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

G 49; GLUCAGON RECEPTOR AGONIST; GLUCOSE; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GLUCONEOGENESIS; HEPATITIS; LIPID DIET; LIVER FAILURE; LIVER FUNCTION; LIVER REGENERATION; MALE; MITOCHONDRIAL BIOGENESIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PARTIAL HEPATECTOMY; PENTOSE PHOSPHATE CYCLE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; NEEDLE BIOPSY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; TREATMENT OUTCOME;

ANIMALS; BIOPSY, NEEDLE; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIVER REGENERATION; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; RANDOM ALLOCATION; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 85010992306     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28962     Document Type: Article

References (49)

1. Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 2016;13:196–205.
2. Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:15532–15538.
3. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72–81.
4. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 2010;176:2–13.
5. Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst Rev 2013;6:CD006935.
6. van Mierlo KM, Schaap FG, Dejong CH, Olde Damink SW. Liver resection for cancer: new developments in prediction, prevention and management of postresectional liver failure. J Hepatol 2016;65:1217–1231.
7. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249–1253.
8. Akoad ME, Pomfret EA. Surgical resection and liver transplantation for hepatocellular carcinoma. Clin Liver Dis 2015;19:381–399.
9. Hoppe S, von Loeffelholz C, Lock JF, Doecke S, Sinn BV, Rieger A, et al. Nonalcoholic steatohepatits and liver steatosis modify partial hepatectomy recovery. J Invest Surg 2015;28:24–31.
10. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003;10:2471–2483.
11. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011;31:1285–1297.
12. Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016:399–408.
13. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679–690.
14. Fernandez-Rojo MA, Restall C, Ferguson C, Martel N, Martin S, Bosch M, et al. Caveolin-1 orchestrates the balance between glucose and lipid-dependent energy metabolism: implications for liver regeneration. Hepatology 2012;55:1574–1584.
15. Johnston DG, Alberti KG. Carbohydrate metabolism in liver disease. Clin Endocrinol Metab 1976;5:675–702.
16. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 1988;21:151–166.
17. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006;30:1729–1736.
18. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 1988;18:499–503.
19. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749–757.
20. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009;58:2258–2266.
21. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113–128.
22. Greene MW, Burrington CM, Ruhoff MS, Johnson AK, Chongkrairatanakul T, Kangwanpornsiri A. PKCδ is activated in a dietary model of steatohepatitis and regulates endoplasmic reticulum stress and cell death. J Biol Chem 2010;285:42115–42129.
23. Martins PN, Theruvath TP, Neuhaus P. Rodent models of partial hepatectomies. Liver Int 2008;28:3–11.
24. Macfarlane DP, Zou X, Andrew R, Morton NM, Livingstone DE, Aucott RL, et al. Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis. Am J Physiol Endocrinol Metab 2011;300:E402–E409.
25. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. Compr Physiol 2013;3:485–513.
26. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47–51.
27. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014;147:1073–1083.
28. Mutanen A, Heikkila P, Lohi J, Raivio T, Jalanko H, Pakarinen MP. Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. J Hepatol 2014;60:183–190.
29. Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005;54:2390–2395.
30. Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab 2014;3:241–251.
31. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004;127:546–558.
32. Battal M, Citgez B, Kartal A, Kemik A, Yildirim P, Ozdenkaya Y, et al. Impact of GLP-1 analogue on oxidative damage and hepatic regeneration in experimental 70% hepatectomy model. Hepatogastroenterology 2015;62:257–260.
33. Itagaki H, Shimizu K, Morikawa S, Ogawa K, Ezaki T. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Pathol 2013;6:2683–2696.
34. Jindal A, Bruzzi S, Sutti S, Locatelli I, Bozzola C, Paternostro C, et al. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). Exp Mol Pathol 2015;99:155–162.
35. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59–69.
36. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012;143:307–320.
37. Wu BT, Dyer RA, King DJ, Richardson KJ, Innis SM. Early second trimester maternal plasma choline and betaine are related to measures of early cognitive development in term infants. PLoS One 2012;7:e43448.
38. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005;115:3554–3563.
39. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malago M, Jalan R, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008;28:767–780.
40. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006;43(Suppl. 1):S45–S53.
41. Studer P, da Silva CG, Revuelta Cervantes JM, Mele A, Csizmadia E, Siracuse JJ, et al. Significant lethality following liver resection in A20 heterozygous knockout mice uncovers a key role for A20 in liver regeneration. Cell Death Differ 2015;22:2068–2077.
42. Sinclair EM, Yusta B, Streutker C, Baggio LL, Koehler J, Charron MJ, et al. Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology 2008;135:2096–2106.
43. Rosa JL, Bartrons R, Tauler A. Gene expression of regulatory enzymes of glycolysis/gluconeogenesis in regenerating rat liver. Biochem J 1992;287:113–116.
44. Tajima T, Goda N, Fujiki N, Hishiki T, Nishiyama Y, Senoo-Matsuda N, et al. HIF-1alpha is necessary to support gluconeogenesis during liver regeneration. Biochem Biophys Res Commun 2009;387:789–794.
45. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007;213:286–300.
46. Mast FD, Rachubinski RA, Aitchison JD. Signaling dynamics and peroxisomes. Curr Opin Cell Biol 2015;35:131–136.
47. Valdecantos MP, Prieto-Hontoria PL, Pardo V, Modol T, Santamaria B, Weber M, et al. Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes. Free Radic Biol Med 2015;84:263–278.
48. Gonzalez-Rodriguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis 2014;5:e1179.
49. Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 2010;30:226–231.